MRI, possibly employing higher field strengths and dedicated breast coils, should be used more often for detecting ductal carcinoma in situ, according to a panel convened by the National Institutes of Health.
MRI, possibly employing higher field strengths and dedicated breast coils, should be used more often for detecting ductal carcinoma in situ, according to a panel convened by the National Institutes of Health.
DCIS is the most common noninvasive lesion of the breast and presents unique challenges for patients and clinicians because the natural course of the untreated disease is not well understood. In DCIS, abnormal cells are found in the breast duct and have not spread outside the duct to other tissues in the breast. This may or may not be a precursor to invasive cancer.
MRI is used as an adjunct screening test in women at high risk, but could gain greater significance when diagnosing DCIS, according to a Sept. 24 statement issued by the panel.
"We're beginning to use MR more commonly in the context of DCIS, with mixed results," said Dr. Denise R. Aberle, a professor of radiology at the University of California, Los Angeles.
MRI is more sensitive than mammography, but there are also issues of under- and over-estimation of size of the carcinoma, involvement of other breast regions, and contralateral breast disease, she said.
The comments came in a conference the NIH Office of Medical Applications of Research and the National Cancer Institute sponsored in Bethesda, MD, Sept. 22-24.
The panel recommended looking at whether higher field strength magnets, dedicated breast coils, and different pulse sequences would improve detection. In addition, there is a strong need to do comparative effectiveness studies in individuals who do and do not undergo MRI, Aberle said.
DCIS is associated with a 10-year survival rate of nearly 100% when treated. Given its nature, and that it may or may not be a precursor for invasive cancer, panelists discussed whether "carcinoma" should be part of its name.
"Although DCIS is relatively indolent in nature, its name includes ‘carcinoma,' so receiving this diagnosis carries with it a substantial negative connotation for both patients and their providers," said Dr. Carmen Allegra, panel chair and chief of hematology and oncology at the University of Florida in Gainesville.
Though pathologists can easily endorse a new name, it's important to keep in mind DCIS cells are both histologically and molecularly identical to invasive cancer cells, according to Dr. Arnold Schwartz, a professor in the pathology department at George Washington University in Washington, DC. Plus, there are many other precursor cancers in the body also called carcinoma in situ, so a name change could affect those as well.
The panel could not say what a new name for DCIS might be as that is a job for pathologists. The panel instead recommended the scientific community take up the issue.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).